<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39398000</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle><i>In silico</i> evaluation of favipiravir-associated potential new drugs against polymerase enzyme of SARS-CoV-2.</ArticleTitle><Pagination><StartPage>e38479</StartPage><MedlinePgn>e38479</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e38479</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2024.e38479</ELocationID><Abstract><AbstractText>Millions of lives have been lost to the deadly SARS-CoV-2 virus. Vaccines and antiviral drugs are essential scientific tools in combating viral infections. This <i>in silico</i> study focused on the RdRp inhibitor favipiravir, exploring new analogs by substituting the fluorine atom on the pyrazine ring with both homocyclic and heterocyclic moieties. Initially, ADME and toxicity properties were assessed using SwissADME and ProTox-II online tools. Ligands <b>L6</b> and <b>L7</b> exhibited high bioavailability and drug-likeness compared to favipiravir. Subsequently, all new analogs were docked into the RdRp active site using AutoDock Vina, demonstrating high affinity compared to favipiravir. Based on optimal ADMET profiles and docking scores, ligands <b>L4</b>, <b>L6</b>, and <b>L7</b> underwent 200 ns MDS using the CHAARM 36 force field in NAMD software to validate docking results. Various trajectory analyses, including RMSD, RMSF, histograms, total number of contacts, and ligand properties, were conducted to gain insights into the interaction patterns between ligands and RdRp. All protein-ligand complexes exhibited greater stability than favipiravir throughout simulations period. This theoretical study suggests that ligands <b>L6</b> and <b>L7</b> could serve as lead candidates for RdRp inhibition. Cell-Based SARS-CoV-2 RdRp Activity Assay is recommended to validate these <i>in silico</i> findings.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saira</LastName><AffiliationInfo><Affiliation>Department of Chemistry, Islamia College Peshawar, Khyber Pakhtunkhwa, 25120, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Khalid</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Islamia College Peshawar, Khyber Pakhtunkhwa, 25120, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Asad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Islamia College Peshawar, Khyber Pakhtunkhwa, 25120, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Ateeq</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Islamia College Peshawar, Khyber Pakhtunkhwa, 25120, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Tanzeel</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Basic Medical Sciences, Khyber Medical University, Peshawar, Khyber Pakhtunkhwa, 25120, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Nasir</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Islamia College Peshawar, Khyber Pakhtunkhwa, 25120, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rashid</LastName><ForeName>Haroon Ur</ForeName><Initials>HU</Initials><AffiliationInfo><Affiliation>Center of Chemical, Pharmaceutical and Food Sciences, Federal University of Pelotas, Pelotas, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zahoor</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Malakand at Chakdara, Dir Lower, Khyber Pakhtunkhwa, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ullah</LastName><ForeName>Riaz</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bari</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, College of Pharmacy King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umar</LastName><ForeName>Muhammad Naveed</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Liverpool, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioinformatics</Keyword><Keyword MajorTopicYN="N">Favipiravir's derivatives</Keyword><Keyword MajorTopicYN="N">RdRp</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39398000</ArticleId><ArticleId IdType="pmc">PMC11467532</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2024.e38479</ArticleId><ArticleId IdType="pii">S2405-8440(24)14510-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>De Wit E., Van Doremalen N., Falzarano D., Munster V.J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 2016;14:523–534. [CrossRef] [PubMed]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097822</ArticleId><ArticleId IdType="pubmed">27344959</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong S.R., Bao L.L. The battle against SARS and MERS coronaviruses: reservoirs and animal models. Anim. Model. Exp. Med. 2018;1:125–133. [CrossRef] [PubMed]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6388065</ArticleId><ArticleId IdType="pubmed">30891557</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehr A.R., Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol. Biol. 2015;1282:1–23. [CrossRef]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369385</ArticleId><ArticleId IdType="pubmed">25720466</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder-Smith A., Teleman M.D., Heng B.H., Earnest A., Ling A.E., Leo Y.S. Asymptomatic SARS coronavirus infection among healthcare workers, Singapore. Emerg. Infect. Dis. 2005;11:1142–1145. [CrossRef]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3371799</ArticleId><ArticleId IdType="pubmed">16022801</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. [CrossRef]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Jartti L., Langen H., Söderlund-Venermo M., Vuorinen T., Ruuskanen O., Jartti T. New respiratory viruses and the elderly. Open Respir. Med. J. 2011;5:61–69. [CrossRef] [PubMed]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3134957</ArticleId><ArticleId IdType="pubmed">21760867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu A., Peng Y., Huang B., Ding X., Wang X., Niu P., Meng J., Zhu Z., Zhang Z., Wang J. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27:325–328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7154514</ArticleId><ArticleId IdType="pubmed">32035028</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Chaolin, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497–506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  International Health regulations emergency committee on novel coronavirus in China. https://www.who.int/news-room/events/detail/2020/01/30/default-calendar/international-health-regulationsemergency-committee-on-novel-coronavirus-in-china Available online:</Citation></Reference><Reference><Citation>World Health Organization  WHO director-general’s opening remarks at the media briefing on COVID-19–11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefingon-covid-19---11-march-2020 Available online:</Citation></Reference><Reference><Citation>WHO COVID-19 dashboard, https://data.who.int/dashboards/covid19/cases, accessed in July 2024.</Citation></Reference><Reference><Citation>The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.". Nature microbiology. 2020;5(4):536–544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095448</ArticleId><ArticleId IdType="pubmed">32123347</ArticleId></ArticleIdList></Reference><Reference><Citation>To K.K., Hung I.F., Chan J.F., Yuen K.Y. From SARS coronavirus to novel animal and human coronaviruses. J. Thorac. Dis. 2013;3:S103–S108. [CrossRef]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3747523</ArticleId><ArticleId IdType="pubmed">23977429</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowell G., Blumberg S., Simonsen L., Miller M.A., Viboud C. Synthesizing data and models for the spread of MERS-CoV, 2013: key role of index cases and hospital transmission. Epidemics. 2014;9:40–51. [CrossRef] [PubMed]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4258236</ArticleId><ArticleId IdType="pubmed">25480133</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Awaidy S.T., Khamis F. Middle East respiratory syndrome coronavirus (MERS-CoV) in Oman: current situation and going forward. Oman Med. J. 2019;34:181–183. [CrossRef] [PubMed]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6505341</ArticleId><ArticleId IdType="pubmed">31110623</ArticleId></ArticleIdList></Reference><Reference><Citation>Khailany Rozhgar A., Safdar Muhamad, Ozaslan Mehmet. Genomic characterization of a novel SARS-CoV-2. Gene reports. 2020;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7161481</ArticleId><ArticleId IdType="pubmed">32300673</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillen Hauke S. Structure and function of SARS-CoV-2 polymerase. Current opinion in virology. 2021;48:82–90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023233</ArticleId><ArticleId IdType="pubmed">33945951</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Lei, et al. RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic. Eur. J. Med. Chem. 2021;213</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7826122</ArticleId><ArticleId IdType="pubmed">33524687</ArticleId></ArticleIdList></Reference><Reference><Citation>https://data.who.int/dashboards/covid19/vaccines?n=c.</Citation></Reference><Reference><Citation>Fragkou P.C., Dimopoulou D. Serious complications of COVID-19 vaccines: a mini-review. Metabolism open. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8556676</ArticleId><ArticleId IdType="pubmed">34746732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseini R., Askari N. A review of neurological side effects of COVID-19 vaccination. Eur. J. Med. Res. 2023;28(1):1–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9959958</ArticleId><ArticleId IdType="pubmed">36841774</ArticleId></ArticleIdList></Reference><Reference><Citation>Borquaye L.S., Gasu E.N., Ampomah G.B., Kyei L.K., Amarh M.A., Mensah C.N., Nartey D., Commodore M., Adomako A.K., Acheampong P., Mensah J.O., Mormor D.B., Aboagye C.I. Alkaloids from Cryptolepis sanguinolenta as potential inhibitors of SARS-CoV-2 viral proteins: an in silico study. Hindawi BioMed. Res. Intern. 2020;5324560 doi: 10.1155/2020/5324560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/5324560</ArticleId><ArticleId IdType="pmc">PMC7512045</ArticleId><ArticleId IdType="pubmed">33029513</ArticleId></ArticleIdList></Reference><Reference><Citation>Pendyalaa B., Patras A. In silico screening of food bioactive compounds to predict potential inhibitors of COVID-19 main protease (mpro) and RNAdependent RNA polymerase (RdRp) Chem. 2020;2:1–11. doi: 10.26434/chemrxiv.12051927.v2.</Citation><ArticleIdList><ArticleId IdType="doi">10.26434/chemrxiv.12051927.v2</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj V., Lee J.-H., Shim J.-J., Lee J. Antiviral activities of 4H-chromen-4-one scaffold-containing flavonoids against SARS–CoV–2 using computational and in vitro approaches. J. Mol. Liquids. 2022;353 doi: 10.1016/j.molliq.2022.118775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molliq.2022.118775</ArticleId><ArticleId IdType="pmc">PMC8849861</ArticleId><ArticleId IdType="pubmed">35194277</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva F.M.A., da Silva K.P.A., de Oliveira L.P.M., Costa E.V., Koolen H.H.F., Pinheiro M.L.B., de Souza A.Q.L., de Souza A.D.L. Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp) Mem. Inst. Oswaldo Cruz. 2020;115 https://doi:10.1590/0074-02760200207 Rio de Janeiro.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0074-02760200207</ArticleId><ArticleId IdType="pmc">PMC7534957</ArticleId><ArticleId IdType="pubmed">33027419</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal R.K., Majeed J., Tonk R., Dhobi M., Patel B., Sharma K., Apparsundaram S. Current targets and drug candidates for prevention and treatment of SARS-CoV-2 M.S. Bekheit et al. European Journal of Medicinal Chemistry 252 (2023) 115292 20 (COVID-19) infection. Rev. Cardiovasc. Med. 2020;21:365–384. https://doi:10.31083/j.rcm.2020.03.118</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.rcm.2020.03.118</ArticleId><ArticleId IdType="pubmed">33070542</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagruti J., Patel a, Sanjeev R., Acharya b, Acharya NiyatiS. Clerodendrum serratum (L.) Moon. – a review on traditional uses, phytochemistry and pharmacological activities. J. Ethnopharmacol. 2014;154:268–285. doi: 10.1016/j.jep.2014.03.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2014.03.071</ArticleId><ArticleId IdType="pubmed">24727551</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb Y.N. Remdesivir: first approval. Drugs. 2020;80:1355–1363. doi: 10.1007/s40265-020-01378-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-020-01378-w</ArticleId><ArticleId IdType="pmc">PMC7459246</ArticleId><ArticleId IdType="pubmed">32870481</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums D.V. Editorial: current status of oral antiviral drug treatments for SARSCoV-2 infection in non-hospitalized patients. Med. Sci. Mon. Int. Med. J. Exp. Clin. Res. 2022;28 https://doi:10.12659/MSM.935952</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.935952</ArticleId><ArticleId IdType="pmc">PMC8729033</ArticleId><ArticleId IdType="pubmed">34972812</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor R. Bowen, Demarest J.F., DeSpirito M., Hartwig A., BielefeldtOhmann H., Walling D.M., Mathis A., Babu Y.S. Activity of Galidesivir in a hamster model of SARS-CoV-2. Viruses. 2022;14:8. doi: 10.3390/v14010008.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14010008</ArticleId><ArticleId IdType="pmc">PMC8780270</ArticleId><ArticleId IdType="pubmed">35062212</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfiky A.A. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248 doi: 10.1016/j.lfs.2020.117477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117477</ArticleId><ArticleId IdType="pmc">PMC7089605</ArticleId><ArticleId IdType="pubmed">32119961</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy O.S., Lai W.-F. Tackling COVID-19 using Remdesivir and Favipiravir as therapeutic options. Chembiochem. 2021;22:939–948. doi: 10.1002/cbic.202000595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbic.202000595</ArticleId><ArticleId IdType="pmc">PMC7675336</ArticleId><ArticleId IdType="pubmed">33031623</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekheit Mohamed S., Panda Siva S., Girgis Adel S. Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2. Eur. J. Med. Chem. 2023;252</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10023213</ArticleId><ArticleId IdType="pubmed">36965227</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuta Y., Takahashi K., Kuno-Maekawa M., Sangawa H., Uehara S., Kozaki K., Nomura N., Egawa H., Shiraki K. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 2005;49:981–986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC549233</ArticleId><ArticleId IdType="pubmed">15728892</ArticleId></ArticleIdList></Reference><Reference><Citation>Manabe T., Kambayashi D., Akatsu H., Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect. Dis. 2021;21(1):1–13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8159019</ArticleId><ArticleId IdType="pubmed">34044777</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin Ruben, Buchwald Stephen L. Palladium-catalyzed Suzuki− Miyaura cross-coupling reactions employing dialkylbiaryl phosphine ligands. Acc. Chem. Res. 2008;41(11):1461–1473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2645945</ArticleId><ArticleId IdType="pubmed">18620434</ArticleId></ArticleIdList></Reference><Reference><Citation>Dua Rajiv, et al. Pharmacological significance of synthetic heterocycles scaffold: a review. Adv. Biol. Res. 2011;5.3:120–144.</Citation></Reference><Reference><Citation>Daina A., Michielin O., Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5335600</ArticleId><ArticleId IdType="pubmed">28256516</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee P., Eckert A.O., Schrey A.K., Preissner R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucl Acids Res Spec Publ. 2018;46(W1):W257–W263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6031011</ArticleId><ArticleId IdType="pubmed">29718510</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2012;64:4–17.</Citation><ArticleIdList><ArticleId IdType="pubmed">11259830</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans David A. History of the harvard ChemDraw project. Angew. Chem. Int. Ed. 2014;42(53):11140–11145.</Citation><ArticleIdList><ArticleId IdType="pubmed">25131311</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Boyle N.M., Banck M., James C.A., Morley C., Vandermeersch T., Hutchison G.R. J. Cheminf. 2011;3:1758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3198950</ArticleId><ArticleId IdType="pubmed">21982300</ArticleId></ArticleIdList></Reference><Reference><Citation>PyRx Virtual Screening Tool, V. 0.9.7; Sarkis Dallakyan, USA. 2015.</Citation></Reference><Reference><Citation>Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Rao Z. Structural basis for RNA replication by the SARS-CoV-2 polymerase. Cell. 2020;182(2):417–428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7242921</ArticleId><ArticleId IdType="pubmed">32526208</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulc C. McGill University; Montreal, QC, Canada: 2020. Molecular Operating Environment (MOE), 2020.09. Chemical Computing Group ULC.</Citation></Reference><Reference><Citation>Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 2009;30:2785–2791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760638</ArticleId><ArticleId IdType="pubmed">19399780</ArticleId></ArticleIdList></Reference><Reference><Citation>Trott O., Olson A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010;31:455–461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041641</ArticleId><ArticleId IdType="pubmed">19499576</ArticleId></ArticleIdList></Reference><Reference><Citation>BIOVIA Discovery Studio Visualizer. BIOVIA Dassault Systems; San Diego, USA: 2020.</Citation></Reference><Reference><Citation>Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998;19(14):1639–1662. doi: 10.1002/(SICI)1096-987X(19981115)19:143.0.CO;2-B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-987X(19981115)19:143.0.CO;2-B</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., MacKerell Jr A.D. CHARMM36 all‐atom additive protein force field: validation based on comparison to NMR data. J. Comput. Chem. 2013;34:2135–2145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3800559</ArticleId><ArticleId IdType="pubmed">23832629</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey W., Dalke A., Schulten K. VMD: visual molecular dynamics. J. Mol. Graph. 1996;14:33–38.</Citation><ArticleIdList><ArticleId IdType="pubmed">8744570</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo S., Kim T., Iyer V.G., Im W. CHARMM‐GUI: a web‐based graphical user interface for CHARMM. J. Comput. Chem. 2008;29:1859–1865.</Citation><ArticleIdList><ArticleId IdType="pubmed">18351591</ArticleId></ArticleIdList></Reference><Reference><Citation>Mark P., Nilsson L. Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. J. Phys. Chem. A. 2001;105:9954–9960.</Citation></Reference><Reference><Citation>Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 2004;25:1605–1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Genheden S., Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expet Opin. Drug Discov. 2015;10(5):449–461. doi: 10.1517/17460441.2015.1032936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17460441.2015.1032936</ArticleId><ArticleId IdType="pmc">PMC4487606</ArticleId><ArticleId IdType="pubmed">25835573</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Abel R., Zhu K., Cao Y., Zhao S., Friesner R.A. The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. Proteins: Struct., Funct., Bioinf. 2011 Oct;79(10):2794–2812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3206729</ArticleId><ArticleId IdType="pubmed">21905107</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivakumar D., et al. Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. J. Chem. Theor. Comput. 2010;6(5):1509–1519.</Citation><ArticleIdList><ArticleId IdType="pubmed">26615687</ArticleId></ArticleIdList></Reference><Reference><Citation>Drwal M.N., Banerjee P., Dunkel M., Wettig M.R., Preissner R. ProTox: a web server for the in silico prediction of rodent oral toxicity. Nucleic Acids Res. 2014;42:W53–W58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086068</ArticleId><ArticleId IdType="pubmed">24838562</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie T.J., Ertl P., Lewis R. The graphical representation of ADME-related molecule properties for medicinal chemists. Drug Discov. Today. 2011;16:65–72.</Citation><ArticleIdList><ArticleId IdType="pubmed">21074634</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovering F., Bikker J., Humblet C. Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 2009;52:6752–6756.</Citation><ArticleIdList><ArticleId IdType="pubmed">19827778</ArticleId></ArticleIdList></Reference><Reference><Citation>Celik Ismail, Erol Meryem, Duzgun Zekeriya. In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase. Mol. Divers. 2021:1–14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7992164</ArticleId><ArticleId IdType="pubmed">33765239</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad J., Ikram S., Ahmad F., Rehman I.U., Mushtaq M. SARS-CoV-2 RNA dependent RNA polymerase (RdRp)–a drug repurposing study. Heliyon. 2020;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7377705</ArticleId><ArticleId IdType="pubmed">32754651</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q., Ming Z., Zhang L. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020;368:779–782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164392</ArticleId><ArticleId IdType="pubmed">32277040</ArticleId></ArticleIdList></Reference><Reference><Citation>Aftab S.O., Ghouri M.Z., Masood M.U., Haider Z., Khan Z., Ahmad A., Munawar N. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach. J. Transl. Med. 2020;18:1–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7339606</ArticleId><ArticleId IdType="pubmed">32635935</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C.J., Tchesnokov E.P., Woolner E., Perry J.K., Feng J.Y., Porter D.P., Götte M. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 2020;295:6785–6797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7242698</ArticleId><ArticleId IdType="pubmed">32284326</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>